Most Likely Laboratory Finding: White Blood Cells in Expressed Prostatic Secretions or Post-Prostatic Massage Urine
This patient most likely has chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), and the most likely abnormal laboratory finding would be white blood cells (WBCs) in expressed prostatic secretions (EPS) or post-prostatic massage urine, consistent with NIH Category IIIA inflammatory CP/CPPS.
Clinical Reasoning
This 62-year-old man presents with a classic constellation of findings for CP/CPPS 1:
- Chronic pelvic pain (4 months duration) in the groin, lower abdomen, and perineum
- Pain worsening with urination and mechanical activity (cycling)
- Transient response to antibiotics (TMP-SMX) that recurred after discontinuation
- Tenderness on palpation of lower abdomen and perineum
- No fever, hematuria, or penile discharge (excluding acute infection or other confusable disorders)
Why CP/CPPS Category IIIA is Most Likely
According to the 2025 AUA guideline, CP/CPPS is defined as pain or discomfort in the pelvic region for at least 3 months within the past 6 months in the absence of identifiable causes 1. The guideline divides CP/CPPS into:
- Category IIIA (inflammatory): WBCs present in EPS, post-prostatic massage urine, or semen
- Category IIIB (non-inflammatory): No WBCs detected
Critically, the guideline states that "to date, there have been no clinically significant differences demonstrated between the 2 subclasses of CP/CPPS (IIIA vs IIIB)" 1, meaning both are treated similarly. However, for a test question asking about laboratory findings, Category IIIA with elevated WBCs is the classic presentation.
Why the Antibiotic Response is Misleading
The transient improvement with TMP-SMX is a red herring. The guideline explicitly states: "CP/CPPS is not due to an ongoing infection" 1. The temporary relief likely represents:
- Anti-inflammatory properties of the antibiotic
- Natural symptom fluctuation
- Placebo effect
The fact that symptoms returned immediately after completing the 5-day course strongly argues against true bacterial prostatitis (NIH Category II), which would require longer treatment (typically 4-6 weeks).
Expected Laboratory Findings
Per the 2025 AUA guideline, basic laboratory evaluation should include 1:
- Urinalysis and mid-stream urine culture: Likely normal or showing sterile pyuria
- Post-void residual (PVR): To exclude bladder outlet obstruction
- If hematuria present: Risk-stratified evaluation per AUA/SUFU guidelines
The key distinguishing finding would be WBCs in prostatic fluid or post-massage urine without evidence of uropathogenic bacteria by standard culture methods 1.
Important Diagnostic Pitfalls
What This is NOT:
- Acute bacterial prostatitis (Category I): Would present with fever, systemic symptoms
- Chronic bacterial prostatitis (Category II): Would show persistent uropathogenic bacteria on culture and require prolonged antibiotics
- Simple UTI: Would not have chronic pelvic/perineal pain or tenderness; would respond definitively to short-course antibiotics
Critical Caveat from Guidelines:
The guideline warns that "strict definitions used in research or clinical trials should be avoided in clinical practice as many patients may be misdiagnosed or experience delays in diagnosis and treatment" 1. This patient's 4-month symptom duration meets diagnostic criteria, but treatment should not be delayed in patients with shorter duration.
Additional Considerations
The guideline emphasizes that CP/CPPS is a diagnosis of exclusion requiring assessment for 1:
- Pelvic floor myalgia (present in this patient with perineal tenderness)
- Neurological, musculoskeletal, or orthopedic abnormalities
- Psychosocial factors (anxiety, depression, stress)
- Overlapping chronic pain conditions (IBS, fibromyalgia, migraine)
Up to 75% of CP/CPPS patients have bladder symptoms including pain with bladder filling, and 70% report pain outside the pelvis 1, making this a complex, multisystem disorder requiring multimodal treatment rather than repeated antibiotics.